Compare NLOP & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NLOP | ALLO |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.3M | 252.9M |
| IPO Year | N/A | 2018 |
| Metric | NLOP | ALLO |
|---|---|---|
| Price | $19.83 | $1.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $46.00 | $8.27 |
| AVG Volume (30 Days) | 340.2K | ★ 6.3M |
| Earning Date | 02-27-2026 | 03-12-2026 |
| Dividend Yield | ★ 96.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $115,901,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.45 | $0.86 |
| 52 Week High | $34.53 | $3.78 |
| Indicator | NLOP | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 58.49 |
| Support Level | $19.16 | $1.56 |
| Resistance Level | $20.00 | $1.84 |
| Average True Range (ATR) | 0.43 | 0.16 |
| MACD | 0.29 | -0.01 |
| Stochastic Oscillator | 87.10 | 67.96 |
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.